⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19951600 | 1.00 | — | — | |
| SCHEMBL3587722 | 0.86 | — | — | |
| SCHEMBL24477568 | 0.77 | — | — | |
| SCHEMBL15038017 | 0.77 | — | — | |
| SCHEMBL3100605 | 0.77 | FFAR2 (0.32) | — | |
| SCHEMBL3592638 | 0.75 | — | — | |
| SCHEMBL3436862 | 0.74 | — | — | |
| SCHEMBL356233 | 0.74 | — | — | |
| SCHEMBL8241010 | 0.74 | — | — | |
| SCHEMBL3108505 | 0.74 | TAAR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | claimed |
| CN-115819417-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2023-03-21 | — | — | CN | claimed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | claimed |
| CN-109923114-B | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2022-11-01 | — | — | CN | claimed |
| US-20210380581-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-09 | — | — | US | claimed |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-04-23 | — | — | US | claimed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | claimed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | claimed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| CN-115819417-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-109923114-B | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-3510032-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORP (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20210380581-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-09 | — | — | US | disclosed |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| EP-2038264-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080132494-A1 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| WO-2008055840-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008000645-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |